AP Biosciences, Inc. (TPEX: 6945)
Health Care · Biotechnology · TW
NT$104.50
+4.92% today · -15.7% 1Y
AP Biosciences, Inc. (TPEX: 6945) operates in the Biotechnology industry within the Health Care sector. The company is valued at $316.78M and employs 37 people.
Over the last twelve months the share price has lost 15.7%, trading between 86.10 and 236.00.
Tweenvest scores AP Biosciences, Inc. across four factors: quality 30/100. Its strongest factor is quality.
6945 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $316.78M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -5.39
- Dividend yield
- —
- Beta (5Y)
- -0.36
- 52-week high
- NT$236.00
- 52-week low
- NT$86.10
- Avg volume (3M)
- —
- Shares outstanding
- 96.99M
- Employees
- 37
- Next earnings
- —
About AP Biosciences, Inc.
AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.
- ISIN
- TW0006945009
- Founded
- 2013
- Listed since
- Jul 14, 2023
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.47 | +0.74% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.00 | +0.04% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.11 | +0.93% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $554.56 | +1.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $835.68 | +0.87% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $159.02 | +14.49% |
Figures last refreshed Aug 18, 2026.